As Congress braces for the largest reform of healthcare in the nation’s history, lost in the debate has been an issue critical to federal and state healthcare budgets, as well as the ability of consumers to afford lifesaving drugs. The issue is whether Congress should grant generic makers of the next generation of medications called “biologics” the same regulatory approval treatment it did for chemical drugs under the 1984 Hatch-Waxman Act.
Healthcare Reform: A Pricey Prescription
President Obama promised this would be the year of health care reform, but many are bracing for what this “reform” could really mean. After much anticipation, Democrats have started to unveil their healthcare reform plans, revealing new policy proposals that would, among other things, expand Medicaid, impose individual and employer mandates, enlarge the almost bankrupt Medicare program, create a new government-run healthcare plan, and cost at least $1 trillion over 10 years. The overall result will inevitably be higher taxes, less patient choice, and ultimately, rationing of care.